We use cookies to provide you with a better experience. By continuing to browse the site you are agreeing to our use of cookies in accordance with our Cookie Policy.
Accept
Home » EMA, FDA Launch Investigation of Zydelig Following Adverse Events
EMA, FDA Launch Investigation of Zydelig Following Adverse Events
The European Medicines Agency and the FDA are launching investigations into Gilead Sciences’ cancer drug Zydelig following an increased rate of serious adverse events, including deaths.
To View This Article:
Login
Subscribe To International Pharmaceutical Regulatory Monitor